Free Trial

National Vision (NASDAQ:EYE) Given New $24.00 Price Target at Wells Fargo & Company

National Vision logo with Consumer Staples background

National Vision (NASDAQ:EYE - Free Report) had its price target boosted by Wells Fargo & Company from $15.00 to $24.00 in a report published on Wednesday morning,Benzinga reports. They currently have an equal weight rating on the stock.

Several other equities analysts have also recently commented on EYE. Citigroup raised shares of National Vision from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $13.00 to $21.00 in a research note on Friday, May 9th. National Bankshares set a $30.00 price objective on shares of National Vision in a research note on Tuesday, July 8th. BMO Capital Markets set a $19.00 price objective on shares of National Vision and gave the company a "market perform" rating in a research note on Monday, May 19th. Loop Capital boosted their price objective on shares of National Vision from $18.00 to $20.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Finally, The Goldman Sachs Group boosted their price target on shares of National Vision from $13.00 to $17.00 and gave the stock a "neutral" rating in a research note on Friday, May 9th. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $23.00.

View Our Latest Stock Report on EYE

National Vision Stock Performance

Shares of NASDAQ EYE traded down $0.32 during midday trading on Wednesday, hitting $25.02. The company's stock had a trading volume of 1,390,162 shares, compared to its average volume of 2,016,429. The stock has a fifty day moving average price of $22.51 and a 200 day moving average price of $15.88. National Vision has a one year low of $9.56 and a one year high of $25.67. The company has a current ratio of 0.54, a quick ratio of 0.35 and a debt-to-equity ratio of 0.29. The firm has a market capitalization of $1.98 billion, a price-to-earnings ratio of -75.82, a P/E/G ratio of 3.72 and a beta of 1.27.

National Vision (NASDAQ:EYE - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.02. National Vision had a negative net margin of 1.40% and a positive return on equity of 3.44%. The company had revenue of $510.32 million for the quarter, compared to analyst estimates of $510.30 million. During the same quarter in the previous year, the firm posted $0.32 earnings per share. The company's quarterly revenue was up 5.7% compared to the same quarter last year. On average, research analysts forecast that National Vision will post 0.31 EPS for the current fiscal year.

Insider Activity

In related news, SVP Ravi Acharya sold 12,000 shares of the company's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $18.75, for a total transaction of $225,000.00. Following the completion of the sale, the senior vice president directly owned 11,700 shares in the company, valued at $219,375. This represents a 50.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 2.70% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. CWM LLC raised its holdings in National Vision by 7.4% in the 2nd quarter. CWM LLC now owns 12,350 shares of the company's stock worth $284,000 after purchasing an additional 856 shares in the last quarter. IFP Advisors Inc bought a new stake in National Vision during the second quarter worth about $83,000. USA Financial Formulas bought a new stake in National Vision during the second quarter worth about $128,000. State of Alaska Department of Revenue boosted its stake in National Vision by 7.8% during the second quarter. State of Alaska Department of Revenue now owns 47,017 shares of the company's stock worth $1,081,000 after acquiring an additional 3,382 shares in the last quarter. Finally, Counterpoint Mutual Funds LLC bought a new stake in National Vision during the second quarter worth about $402,000.

National Vision Company Profile

(Get Free Report)

National Vision Holdings, Inc, through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services.

Read More

Analyst Recommendations for National Vision (NASDAQ:EYE)

Should You Invest $1,000 in National Vision Right Now?

Before you consider National Vision, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and National Vision wasn't on the list.

While National Vision currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines